What Does the Historical and Current In Silico Clinical Trials Market Size Trend Indicate?
The in silico clinical trials market has seen considerable growth due to a variety of factors.
•In recent times, the market size for in silico clinical trials has seen robust growth. The market is set to increase from $3.51 billion in 2024 to $3.77 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.3%.
The growth during the historical period is a result of factors such as an increase in the availability of medical data, changes in regulatory frameworks for virtual trials, advancements in computing power, the surge in healthcare digitization, and broader implementation of precision medicine initiatives.
How Will the In Silico Clinical Trials Market Size Evolve over the Forecast Period?
The in silico clinical trials market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for in silico clinical trials is predicted to experience an accelerated expansion in the coming years. By 2029, it is projected to increase to $5.64 billion, with a compound annual growth rate (CAGR) of 10.6%.
Factors contributing to growth during the forecast period include the increasing need for speedier drug development procedures, the implementation of virtual patient groups in clinical trials, the broadening of digital twin technologies, and a surge in official approval for in silico trials. During the forecast period, notable trends such as the creation of more lifelike virtual patient models, incorporating real-world evidence in in silico trials, prioritizing decentralized and patient-oriented trial structures, a boost in the employment of digital biomarkers, and an intensified attention on personalized medicine in virtual trials are expected to emerge.
What Are The Core Factors Supporting Growth In The In Silico Clinical Trials Market?
The increase in the occurrence of infectious diseases is projected to propel the in silico clinical trials market's advancement. Urbanization and overcrowding, climate alteration, microbial evolution, and escalated travel contribute to this growing prevalence of infectious diseases. In silico clinical trials use computational models and simulations to expedite the creation of infectious disease treatments. This allows scientists to investigate disease mechanisms, anticipate drug effectiveness, and enhance clinical trial configurations, ultimately augmenting patient results and propelling responses to public health. For example, gov.uk, an information portal from the UK public sector, reported 3,805 newly diagnosed HIV cases in England during 2022, reflecting a 22% surge from the 3,118 cases in 2021 and a 26% leap from the 3,026 in 2020. Consequently, the escalating occurrence of infectious diseases fuels the in silico clinical trials market progress.
What Are The Major Segments Within The Global In Silico Clinical Trials Market?
The in silico clinical trials market covered in this report is segmented –
1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Therapeutic Area: Oncology, Infectious Disease, Hematology, Cardiology, Dermatology, Neurology, Diabetes, Other Therapeutic Areas
3) By Industry: Medical Devices, Pharmaceutical
Subsegments:
1) By Phase I: Safety And Dosage Trials, Pharmacokinetics And Pharmacodynamics Studies
2) By Phase II: Efficacy Trials, Dose-Response Studies
3) By Phase III: Comparative Effectiveness Trials, Large-Scale Efficacy Studies
4) By Phase IV: Post- marketing Surveillance, Long-Term Safety Studies
Pre-Book The In Silico Clinical Trials Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The In Silico Clinical Trials Market?
One significant trend emerging in the in silico clinical trials market is the development of strategic alliances. Major players in this field are forming partnerships to enhance their market stance. For example, in March 2023, US-based clinical research organization (CRO), Premier Research, formed an alliance with an American firm known as InSilicoTrials, which specializes in drug-development modeling and simulation. This collaboration allows Premier Research to create more secure, quicker, and efficient routes to obtain approval for treatments for rare diseases. Additionally, in March 2022, 4P-Pharma, a biotech firm located in France, joined forces with QuantHealth, an AI firm based in Israel. This collaboration allows them to perform patient-focused drug simulations to expedite and make drug development safer. As a result, 4P-Pharma can carry out in silico clinical trials of main drug candidates and hasten clinical trial simulations via in-depth molecular drug data and real-world data (RWD).
Who Are the Key Players in the In Silico Clinical Trials Market?
Major companies operating in the in silico clinical trials market include:
• Dassault Systemes SE
• Clarivate plc
• Evotec A.G
• Evidera
• Certara Inc.
• Abzena Limited
• Selvita
• Simulations Plus Inc.
• Insilico Medicine Inc.
• AnyLogic Company
• Biomax Informatics
• GNS Healthcare Inc.
• 4P-Pharma
• Nuventra Pharma Sciences
• Archimedes
• Novadiscovery Sas
• Rosa & Co.
• In Silico Biosciences
• Leadscope
• Biognos Ab
• BioNova
• Immunetrics Inc.
• InSilicoTrials
• Physiomics plc
• InhibOx
• Entelos
What Is The Most Dominant Region In The In Silico Clinical Trials Market?
North America was the largest region in the in silico clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the in silico clinical trials market report during the forecast period. The regions covered in the in silico clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
